My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
Navigating the Speed Bumps and Driving Decisions: A Roadmap for Integrating Acquired Alliances
Tell a Friend About This EventTell a Friend
Navigating the Speed Bumps and Driving Decisions: A Roadmap for Integrating Acquired Alliances

When: Thursday, April 14, 2016
12:00 PM – 1:00 PM Eastern US
Where: Online Webinar
United States
Contact: Brendan Ward

Online registration is closed.
« Go to Upcoming Event List  

When a company is acquired, so too are its alliances. Often, there is little insight into the acquired company's portfolio; not even into its alliance contracts. So once the deal closes, it becomes the alliance professional's responsibility to guide, inform, and manage the decision-making of the integration team and executive leadership—sometimes including decisions or requirements to divest, while establishing new alliance relationships and maintaining contractual obligations.

This session takes a deep dive into how to order the process of investigation, inquiry, and engagement of key stakeholders when alliances are acquired rather than chosen. Learn the speed bumps to expect and tips for navigating:

  • Communicating internally and with partners to build alliances teams, establish governance, and drive value
  • Divestiture and termination decisions that respect the partner and individuals involved
  • The not glamorous, but oh-so-real business challenges of integration that can cause blips in reporting and cash flow

Speaker Bio

Katherine Kendrick, CA-AM
Director Alliance Management
Elanco, Eli Lilly and Company

Katherine Kendrick is Elanco's Director of Alliance Management for Research and Development managing the strategic alliance portfolio of external innovation and mergers and acquisitions. Katherine joined Elanco in 2015 and is leading the establishment of alliance management capabilities within this rapidly growing division of Eli Lilly. As a member of the Eli Lilly and Company Office of Alliance of Management, Katherine ensured the delivery of Diabetes pharmaceutical and device development partnerships and commercial relationships.

In addition to Katherine's more than 15 years of pharmaceutical experience and emerging market expertise her leadership in the animal health space at Elanco is an exciting application of her B.S. in Biomedical Science from Texas A&M University.

For more information email us at or call +1-781-562-1630